

09/847 048

C67C

### Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Services with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Mailing Date: April 12, 2006

Signed by: Lhet Chuakay

Lhet Chuakay

Patent

Attorney's Docket No. P-091-US1

Customer No. 27038

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: U.S. 6,872,804 B2

Issued: March 29, 2005

Name of Patentee: MU

Title: GLYCOPEPTIDE DISULFIDE AND  
THIOESTER DERIVATIVES

Confirmation No. 5200

**Certificate**

**APR 19 2006**

**of Correction**

### **REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR PTO MISTAKE (37 C.F.R. §1.322(a))**

ATTN: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Assignee hereby requests that a certificate of correction be issued for the above-identified issued U.S. patent. The requested corrections are shown on the attached PTO/SB/44 form (1 page), which form is being submitted herewith in duplicate in a form suitable for printing.

#### **I. CORRECTIONS REQUESTED FOR PTO MISTAKE PURSUANT TO 37 C.F.R. § 1.322(A)**

The following mistakes in the issued U.S. patent are due to PTO error:

(1) In Column 38, at line 32, (Claim 1), "cycloalkenylene" should read

-- cycloalkenylene, --.

**APR 20 2006**

This mistake is clearly disclosed in the records of the Office at, for example, page 2, text line 5<sup>th</sup> from the bottom of the page, of the Amendment submitted by Applicants on July 9, 2004.

(2) In Column 38, at lines 34-35, (Claim 1), "-C(O)-cycloallkenylene" should read -- -C(O)-cycloalkenylene, --.

This mistake is clearly disclosed in the records of the Office at, for example, page 2, text line 2nd from the bottom of the page, of the Amendment submitted by Applicants on July 9, 2004.

(3) In Column 38, at line 36, (Claim 1), "or heterocyclene;" should read -- or -C(O)-heterocyclene; --.

This mistake is clearly disclosed in the records of the Office at, for example, page 2, text line at the bottom of the page, of the Amendment submitted by Applicants on July 9, 2004.

(4) In Column 38, at line 37, (Claim 1), "cydoalkenyl," should read -- cycloalkenyl, --.

This mistake is clearly disclosed in the records of the Office at, for example, page 3, text line 2, of the Amendment submitted by Applicants on July 9, 2004.

(5) In Column 38, at line 39, (Claim 1), "stereoisonier," should read -- stereoisomer, --.

This mistake is clearly disclosed in the records of the Office at, for example, page 3, text line 5, of the Amendment submitted by Applicants on July 9, 2004.

Since the above errors are due to USPTO mistake, Assignee respectfully requests that a timely Certificate of Correction be issued to correct these mistakes.

APR 20 2005

II. FEE PAYMENT

Since this paper is being submitted to correct errors by the USPTO, no fee is believed to be required. However, if a fee is determined to be necessary, the Commissioner is hereby authorized to charge any fees required by this paper, and to charge any additional fees and credit any overpayment to Deposit Account No. 50-0344.

III. MAILING ADDRESS FOR CERTIFICATE

A certificate of correction issued for this U.S. patent should be sent to the following address:

Jeffrey A. Hagenah, Esq.  
Theravance, Inc.  
901 Gateway Boulevard  
South San Francisco, CA 94080

IV. STATEMENT UNDER 37 C.F.R. § 3.73(B)


Theravance, Inc., a corporation, states that it is the assignee of the entire right, title and interest in the patent identified above by virtue of an Assignment from the inventors to Advanced Medicine, Inc. recorded on September 17, 2001, at Reel 012169 and Frame 0279; and by virtue of a merger conveying the entire right, title and interest from Advanced Medicine, Inc. to Theravance, Inc., recorded on June 14, 2002, at Reel 013003 and Frame 0075.

I, Jeffrey A. Hagenah, Assistant Secretary of Theravance, Inc., state that I am empowered to sign this statement on behalf of the assignee.

Respectfully submitted,  
THERAVANCE, INC.

Date: April 11, 2006

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078

  
Jeffrey A. Hagenah, Ph.D., Esq.  
Reg. No. 35,175  
Direct Tel: (650) 808-6406

APR 20 2006

## UNITED STATES PATENT AND TRADEMARK OFFICE

### CERTIFICATE OF CORRECTION

PATENT NO : US 6,872,804 B2

Page 1 of 1

APPLICATION NO. : 09/847,048

ISSUE DATE : March 29, 2005

INVENTOR(S) : Mu

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

**Column 38**

line 32, (Claim 1), "cycloalkenylene" should read -- cycloalkenylene, --;  
lines 34-35, (Claim 1), "-C(O)-cycloallcenylene" should read -- -C(O)-cycloalkenylene, --;  
line 36, (Claim 1), "or heterocyclene;" should read -- or -C(O)-heterocyclene; --;  
line 37, (Claim 1), "cydoalkenyl," should read -- cycloalkenyl, --; and  
line 39, (Claim 1), "stereoisonier," should read -- stereoisomer, --.

**MAILING ADDRESS OF SENDER (Please do not use customer number below):**

Jeffrey A. Hagenah, Esq.  
Theravance, Inc.  
901 Gateway Boulevard  
South San Francisco, CA 94080

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAY 20 2006